NVSEF - Novartis AG

Other OTC - Other OTC Delayed Price. Currency in USD

Novartis AG

Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
http://www.novartis.com

SectorHealthcare
IndustryDrug Manufacturers—General
Full Time Employees109,000

Key Executives

NameTitlePayExercisedYear Born
Dr. Vasant NarasimhanChief Exec. OfficerN/AN/A1976
Mr. Harry KirschChief Financial OfficerN/AN/A1965
Mr. Steffen Lang Ph.D.Global Head of Technical OperationsN/AN/A1967
Ms. Shannon Thyme KlingerGroup Gen. CounselN/AN/A1971
Dr. Klaus MoosmayerChief Ethics, Risk & Compliance OfficerN/AN/A1968
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has collaboration agreements with Pear Therapeutics; Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute; Science 37; Bill & Melinda Gates Foundation; Amgen; University of California, Berkeley; Bristol-Myers Squibb; Drugs for Neglected Diseases initiative (DNDi); TScan Therapeutics; and Dyno Therapeutics Inc. The company was founded in 1895 and is headquartered in Basel, Switzerland.

Corporate Governance

Novartis AG’s ISS Governance QualityScore as of December 7, 2019 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 7; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.